Publication of impact on health-related quality of life from 3 year data with vosoritide. These data suggest that after 3 years of treatment, vosoritide demonstrates a…
Since the approval of vosoritide in 2021, a need was created for a treatment guideline for support clinicians. An international collaborative of leading experts and patient…
Achondroplasia is the most common skeletal dysplasia and is characterized by a variety of medical, functional and psychosocial challenges across the lifespan. There is variability in…
Despite the recognized expertise of pediatric endocrinologists, children with skeletal dysplasias have not been consistently managed by these physicians. Growth-altering treatments have broadened the role of…
Achondroplasia growth charts included in this article. Achondroplasia is the most common genetic skeletal disorder causing disproportionate short stature/dwarfism. Common additionalfeatures include spinal stenosis, midface retrusion,…
Constitutional Growth Delay and Familial Short Stature: A Guide for Families What is Short Stature? Doctors usually define short stature based on standard growth charts, rather…
A mini-review on cost-conscious growth-promoting treatment.
PES Drugs and Therapeutics and Ethics committees present guidelines for Growth Hormone and Insulin-like Growth Factor-I Treatment in Children and Adolescents: Growth Hormone Deficiency, Idiopathic Short Stature, and Primary Insulin-Like Growth Factor-I Deficiency.
A review of published data regarding the use of aromatase inhibitors in pediatrics.